Myriad Genetics Study Published In JCO Precision Oncology Shows Co's Prolaris Test Can Predict Benefit Of Hormone Therapy Treatment In Men With Localized Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics' Prolaris Test has been shown to predict the benefit of adding hormone therapy to radiation therapy in men with localized prostate cancer, according to a study published in JCO Precision Oncology. This test is the only biomarker test that quantifies the benefits of combining androgen deprivation therapy with radiation therapy.
May 16, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics' Prolaris Test has been validated by a study published in JCO Precision Oncology, showing it can predict the benefit of adding hormone therapy to radiation therapy in men with localized prostate cancer. This could enhance the test's adoption and Myriad's market position.
The study's publication in a reputable journal like JCO Precision Oncology provides strong validation for Myriad Genetics' Prolaris Test. This could lead to increased adoption of the test, positively impacting Myriad's market position and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100